Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus CEFADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus CEFADYL.
ANCEF vs CEFADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic